1. Home
  2. AVBP vs BFS Comparison

AVBP vs BFS Comparison

Compare AVBP & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVBP
  • BFS
  • Stock Information
  • Founded
  • AVBP 2021
  • BFS 1993
  • Country
  • AVBP United States
  • BFS United States
  • Employees
  • AVBP N/A
  • BFS N/A
  • Industry
  • AVBP
  • BFS Real Estate Investment Trusts
  • Sector
  • AVBP
  • BFS Real Estate
  • Exchange
  • AVBP NYSE
  • BFS Nasdaq
  • Market Cap
  • AVBP 862.8M
  • BFS 830.6M
  • IPO Year
  • AVBP 2024
  • BFS 1993
  • Fundamental
  • Price
  • AVBP $18.66
  • BFS $31.71
  • Analyst Decision
  • AVBP Strong Buy
  • BFS Strong Buy
  • Analyst Count
  • AVBP 8
  • BFS 1
  • Target Price
  • AVBP $38.38
  • BFS $45.50
  • AVG Volume (30 Days)
  • AVBP 239.9K
  • BFS 59.1K
  • Earning Date
  • AVBP 08-13-2025
  • BFS 08-12-2025
  • Dividend Yield
  • AVBP N/A
  • BFS 7.42%
  • EPS Growth
  • AVBP N/A
  • BFS N/A
  • EPS
  • AVBP N/A
  • BFS 1.47
  • Revenue
  • AVBP N/A
  • BFS $274,011,000.00
  • Revenue This Year
  • AVBP N/A
  • BFS $10.48
  • Revenue Next Year
  • AVBP N/A
  • BFS $6.52
  • P/E Ratio
  • AVBP N/A
  • BFS $21.64
  • Revenue Growth
  • AVBP N/A
  • BFS 5.04
  • 52 Week Low
  • AVBP $15.47
  • BFS $31.25
  • 52 Week High
  • AVBP $36.37
  • BFS $42.39
  • Technical
  • Relative Strength Index (RSI)
  • AVBP 29.95
  • BFS 31.79
  • Support Level
  • AVBP $21.10
  • BFS $32.65
  • Resistance Level
  • AVBP $22.29
  • BFS $32.98
  • Average True Range (ATR)
  • AVBP 1.02
  • BFS 0.65
  • MACD
  • AVBP -0.29
  • BFS -0.17
  • Stochastic Oscillator
  • AVBP 2.38
  • BFS 4.12

About AVBP ARRIVENT BIOPHARMA INC

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

Share on Social Networks: